Biology Reference
In-Depth Information
Lin, E.Y., Li, J.F., Bricard, G., Wang, W., Deng, Y., Sellers, R., Porcelli, S.A., Pollard, J.W.,
2007. Vascular endothelial growth factor restores delayed tumor progression in tumors
depleted of macrophages. Mol. Oncol. 1, 288-302.
Linde, N., Lederle, W., Depner, S., van, R.N., Gutschalk, C.M., Mueller, M.M., 2012. Vascu-
lar endothelial growth factor induced skin carcinogenesis depends on recruitment and
alternative activation of macrophages. J. Pathol. 227, 17-28.
Lissbrant, I.F., Stattin, P., Wikstrom, P., Damber, J.E., Egevad, L., Bergh, A., 2000. Tumor asso-
ciated macrophages in human prostate cancer: relation to clinicopathological variables
and survival. Int. J. Oncol. 17, 445-451.
Loberg, R.D., Day, L.L., Harwood, J., Ying, C., St John, L.N., Giles, R., Neeley, C.K., Pienta,
K.J., 2006. CCL2 is a potent regulator of prostate cancer cell migration and proliferation.
Neoplasia 8, 578-586.
Loberg, R.D., Ying, C., Craig, M., Yan, L., Snyder, L.A., Pienta, K.J., 2007. CCL2 as an
important mediator of prostate cancer growth
in vivo
through the regulation of macro-
phage infiltration. Neoplasia 9, 556-562.
Locati, M., Deuschle, U., Massardi, M.L., Martinez, F.O., Sironi, M., Sozzani, S., Bartfai, T.,
Mantovani, A., 2002. Analysis of the gene expression profile activated by the CC chemo-
kine ligand 5/RANTES and by lipopolysaccharide in human monocytes. J. Immunol.
168, 3557-3562.
Loges, S., Schmidt, T., Carmeliet, P., 2009. Antimyeloangiogenic” therapy for cancer by
inhibiting PlGF. Clin. Cancer Res. 15, 3648-3653.
Luo,Y.P., Zhou, H., Krueger, J., Kaplan, C., Liao, D., Markowitz, D., Liu, C., Chen, T., Chuang,
T.H., Xiang, R., Reisfeld, R.A., 2010. The role of proto-oncogene Fra-1 in remodeling
the tumor microenvironment in support of breast tumor cell invasion and progression.
Oncogene 29, 662-673.
Lyden, D., Hattori, K., Dias, S., Costa, C., Blaikie, P., Butros, L., Chadburn, A., Heissig, B.,
Marks, W., Witte, L., Wu, Y., Hicklin, D., Zhu, Z., Hackett, N.R., Crystal, R.G., Moore,
M.A., Hajjar, K.A., Manova, K., Benezra, R., Rafii, S., 2001. Impaired recruitment of
bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor
angiogenesis and growth. Nat. Med. 7, 1194-1201.
Makitie, T., Summanen, P., Tarkkanen, A., Kivela, T., 2001. Tumor-infiltrating macrophages
(CD68(+) cells) and prognosis in malignant uveal melanoma. Invest Ophthalmol. Vis.
Sci. 42, 1414-1421.
Mantovani, A., 2008. From phagocyte diversity and activation to probiotics: back to Metch-
nikoff. Eur. J. Immunol. 38, 3269-3273.
Mantovani, A., Sica, A., 2010. Macrophages, innate immunity and cancer: balance, tolerance,
and diversity. Curr. Opin. Immunol. 22, 231-237.
Mantovani, A., Sozzani, S., Locati, M., Allavena, P., Sica, A., 2002. Macrophage polarization:
tumor-associated macrophages as a paradigm for polarized M2 mononuclear phago-
cytes. Trends Immunol. 23, 549-555.
Mantovani, A., Allavena, P., Sica, A., 2004. Tumour-associated macrophages as a prototypic
type II polarised phagocyte population: role in tumour progression. Eur. J. Cancer 40,
1660-1667.
Martinez, F.O., Gordon, S., Locati, M., Mantovani, A., 2006. Transcriptional profiling of the
human monocyte-to-macrophage differentiation and polarization: new molecules and
patterns of gene expression. J. Immunol. 177, 7303-7311.
Mayer, R.J., 2004. Two steps forward in the treatment of colorectal cancer. N. Engl. J. Med.
350, 2406-2408.
Mohamed, M.M., Sloane, B.F., 2006. Cysteine cathepsins: multifunctional enzymes in cancer.
Nat. Rev. Cancer 6, 764-775.
Murdoch, C., Lewis, C.E., 2005. Macrophage migration and gene expression in response to
tumor hypoxia. Int. J. Cancer 117, 701-708.
Search WWH ::
Custom Search